Stocks and Investing Stocks and Investing
Mon, January 30, 2023
Sun, January 29, 2023
Fri, January 27, 2023

Michael Ulz Downgraded (TSHA) to Hold and Held Target at $3 on, Jan 27th, 2023


Published on 2024-10-28 01:10:52 - WOPRAI, Michael Ulz
  Print publication without navigation


Michael Ulz of Morgan Stanley, Downgraded "Taysha Gene Therapies, Inc." (TSHA) to Hold and Held Target at $3 on, Jan 27th, 2023.

Michael has made no other calls on TSHA in the last 4 months.



There are 7 other peers that have a rating on TSHA. Out of the 7 peers that are also analyzing TSHA, 1 agrees with Michael's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Salveen Richter of "Goldman Sachs" Downgraded from Strong Buy to Hold and Decreased Target to $3 on, Wednesday, November 9th, 2022


These are the ratings of the 6 analyists that currently disagree with Michael


  • Silvan Tuerkcan of "JMP Securities" Maintained at Buy with Decreased Target to $6 on, Thursday, January 19th, 2023
  • Yanan Zhu of "Wells Fargo" Maintained at Buy with Decreased Target to $10 on, Wednesday, January 4th, 2023
  • Geulah Livshits of "Chardan Capital" Maintained at Strong Buy with Decreased Target to $16 on, Wednesday, November 9th, 2022
  • Gil Blum of "Needham" Maintained at Strong Buy with Decreased Target to $16 on, Wednesday, November 9th, 2022
  • Whitney Ijem of "Canaccord Genuity" Initiated at Strong Buy and Held Target at $16 on, Tuesday, November 8th, 2022
  • Jack Allen of "Baird" Maintained at Buy with Decreased Target to $21 on, Wednesday, October 26th, 2022
Contributing Sources